Polyprodrug Nanomedicines: An Emerging Paradigm for Cancer Therapy
- PMID: 34693571
- DOI: 10.1002/adma.202107434
Polyprodrug Nanomedicines: An Emerging Paradigm for Cancer Therapy
Abstract
Nanomedicines have the potential to provide advanced therapeutic strategies in combating tumors. Polymer-prodrug-based nanomedicines are particularly attractive in cancer therapies owing to the maximum drug loading, prolonged blood circulation, and reduced premature leakage and side effects in comparison with conventional nanomaterials. However, the difficulty in precisely tuning the composition and drug loading of polymer-drug conjugates leads to batch-to-batch variations of the prodrugs, thus significantly restricting their clinical translation. Polyprodrug nanomedicines inherit the numerous intrinsic advantages of polymer-drug conjugates and exhibit well-controlled composition and drug loading via direct polymerization of therapeutic monomers, representing a promising nanomedicine for clinical tumor therapies. In this review, recent advances in the development of polyprodrug nanomedicines are summarized for tumor elimination. Various types of polyprodrug nanomedicines and the corresponding properties are first summarized. The unique advantages of polyprodrug nanomedicines and their key roles in various tumor therapies are further highlighted. Finally, current challenges and the perspectives on future research of polyprodrug nanomedicines are discussed.
Keywords: cancer therapy; drug delivery; nanomedicine; polyprodrug; self-assembly.
© 2021 Wiley-VCH GmbH.
Similar articles
-
Zwitterionic-to-cationic charge conversion polyprodrug nanomedicine for enhanced drug delivery.Theranostics. 2020 May 17;10(15):6629-6637. doi: 10.7150/thno.47849. eCollection 2020. Theranostics. 2020. PMID: 32550894 Free PMC article.
-
Charge-conversional click polyprodrug nanomedicine for targeted and synergistic cancer therapy.J Control Release. 2023 Apr;356:567-579. doi: 10.1016/j.jconrel.2023.03.019. Epub 2023 Mar 17. J Control Release. 2023. PMID: 36924894
-
Controlled drug delivery with nanoassemblies of redox-responsive prodrug and polyprodrug amphiphiles.J Control Release. 2020 Oct 10;326:276-296. doi: 10.1016/j.jconrel.2020.07.010. Epub 2020 Jul 17. J Control Release. 2020. PMID: 32682899 Review.
-
Polyprodrug nanomedicine for chemiexcitation-triggered self-augmented cancer chemotherapy and gas therapy.Biomaterials. 2024 Sep;309:122606. doi: 10.1016/j.biomaterials.2024.122606. Epub 2024 May 9. Biomaterials. 2024. PMID: 38776593
-
Stimuli-responsive prodrug-based cancer nanomedicine.EBioMedicine. 2020 Jun;56:102821. doi: 10.1016/j.ebiom.2020.102821. Epub 2020 Jun 7. EBioMedicine. 2020. PMID: 32505922 Free PMC article. Review.
Cited by
-
Research progress of calcium carbonate nanomaterials in cancer therapy: challenge and opportunity.Front Bioeng Biotechnol. 2023 Sep 21;11:1266888. doi: 10.3389/fbioe.2023.1266888. eCollection 2023. Front Bioeng Biotechnol. 2023. PMID: 37811375 Free PMC article. Review.
-
Pharmacogenomics influence on MDR1-associated cancer resistance and innovative drug delivery approaches: advancing precision oncology.Med Oncol. 2025 Feb 6;42(3):67. doi: 10.1007/s12032-025-02611-w. Med Oncol. 2025. PMID: 39913003 Review.
-
A self-reinforced activatable photosensitizer prodrug enabling synergistic photodynamic and chemotherapy.Smart Mol. 2024 Jun 14;2(4):e20240005. doi: 10.1002/smo.20240005. eCollection 2024 Dec. Smart Mol. 2024. PMID: 40626272 Free PMC article.
-
Experience with Photodynamic Therapy Using Indocyanine Green Liposomes for Refractory Cancer.J Pers Med. 2022 Jun 24;12(7):1039. doi: 10.3390/jpm12071039. J Pers Med. 2022. PMID: 35887536 Free PMC article.
-
New-generation advanced PROTACs as potential therapeutic agents in cancer therapy.Mol Cancer. 2024 May 21;23(1):110. doi: 10.1186/s12943-024-02024-9. Mol Cancer. 2024. PMID: 38773495 Free PMC article. Review.
References
-
- R. K. Jain, T. Stylianopoulos, Nat. Rev. Clin. Oncol. 2010, 7, 653.
-
- B. Y. S. Kim, J. T. Rutka, W. C. W. Chan, N. Engl. J. Med. 2010, 363, 2434.
-
- T. Lammers, S. Aime, W. E. Hennink, G. Storm, F. Kiessling, Acc. Chem. Res. 2011, 44, 1029.
-
- J. Shi, P. W. Kantoff, R. Wooster, O. C. Farokhzad, Nat. Rev. Cancer 2017, 17, 20.
-
- A. Wicki, D. Witzigmann, V. Balasubramanian, J. Huwyler, J. Controlled Release 2015, 200, 138.
Publication types
MeSH terms
Substances
Grants and funding
- 2021Z99CFZ007/Tsinghua University Spring Breeze Fund
- NUHSRO/2020/133/Startup/08/Startup Funding from Tsinghua University
- NUHSRO/2021/034/TRP/09/Nanomedicine/NUS School of Medicine Nanomedicine Translational Research Programme
- NUHSRO/2021/044/Kickstart/09/LOA/NUS School of Medicine Kickstart Initiative
- 0121/ 2018/A3/Science and Technology Development Fund
- 0007/2020/A/Science and Technology Development Fund
- MYRG2017-00010-ICMS/University of Macau
- MYRG2019-00059-ICMS/University of Macau
- 21871301/National Natural Science Foundation of China
- 22071275/National Natural Science Foundation of China
- 51973038/National Natural Science Foundation of China
- 91963107/National Natural Science Foundation of China
LinkOut - more resources
Full Text Sources
Medical